ReviewNutrients2026
Alginate Oligosaccharides in Lipid Metabolism: A Dual-Action Marine Prebiotic.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alginate oligosaccharides (AOS) are degradation products of brown seaweed alginate, known as dietary bioactive components and used as health-beneficial nutrients. Unlike conventional prebiotics such as fructo-oligosaccharides, galacto-oligosaccharides, and xylo-oligosaccharides, AOS carry carboxyl groups and are negatively charged at physiological pH. This narrative review uses charge as an organizing framework for understanding their lipid-regulating effects. Neutral oligosaccharides act mainly through gut microbial fermentation, whereas charged oligosaccharides can also act on host cells directly, although charge and backbone structure cannot be fully separated in the available studies. The gut-dependent actions of AOS (microbiota modulation, short-chain fatty acid production, bile acid metabolism, and barrier protection) and the direct actions supported mainly by in vitro evidence or parenteral administration in animals, including AMP-activated protein kinase (AMPK) activation, brown adipose tissue thermogenesis, and candidate receptor-mediated effects, are discussed, although the systemic exposure achievable after oral intake remains to be established. The beneficial functions of AOS depend on structural parameters such as degree of polymerization, M/G ratio, and terminal unsaturation; the AOS product approved in China in 2026 is produced by acid hydrolysis, and its relationship to the more active unsaturated forms remains unresolved. Structurally defined AOS are to be developed for nutritional supplementation and as potential candidates for clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.